Clinical Trial Update: Nilotinib in PH+, BCR-, ABL+ CML Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for nilotinib in Philadelphia-positive, BCR-ABL-positive chronic myeloid leukemia patients, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: COMPLETED